Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11165MR)

This product GTTS-WQ11165MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IFNAR1 gene. The antibody can be applied in Diffuse scleroderma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000629.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454
UniProt ID P17181
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ11165MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12179MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MORAb-022
GTTS-WQ7537MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GC-182
GTTS-WQ14494MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RYI-018
GTTS-WQ9897MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA KB001-A
GTTS-WQ4619MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986016
GTTS-WQ13375MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PR-1498487
GTTS-WQ2750MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG162
GTTS-WQ10942MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MBG-453
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW